+1.14%
Today
Loading 1D prices…
Company profile
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
850
Fiscal year end
1231
CIK
1490978
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| AVBPArriVent BioPharma Inc. Common Stock | $1.4B | $0.00 | — | -$4.32 | +1.08% | Buy |
| RAREUltragenyx Pharmaceutical Inc. Common Stock | $1.4B | $673M | -85.44% | -$5.83 | -0.69% | Hold |
| LBRXLB Pharmaceuticals Inc Common Stock | $1.4B | $0.00 | — | -$3.13 | -3.50% | Buy |
| PAHCPhibro Animal Health Corporation Class A Common Stock | $1.4B | $1.5B | +6.57% | $2.43 | -2.60% | Hold |
| LTGOLatigo Biotherapeutics Inc. Common Stock | $1.5B | $0.00 | — | -$2.48 | +2.69% | Buy |